Leflunomide Sandoz (Leflunomide)

Leflunomide is converted in the body to teriflunomide, which selectively blocks the enzyme dihydroorotate dehydrogenase. This inhibition curtails de novo pyrimidine synthesis, suppressing the proliferation of activated lymphocytes and thereby diminishing the autoimmune inflammatory response that drives joint damage.

The appropriate dose of Leflunomide Sandoz is determined by the prescribing physician based on the individual’s clinical condition, disease severity, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Leflunomide is classified as pregnancy category X because it is teratogenic. It is contraindicated during pregnancy and must be discontinued before conception. The drug is also not recommended while breastfeeding, as it may pass into breast milk and affect the infant.

To order Leflunomide Sandoz, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Leflunomide is often compared with methotrexate, another first‑line DMARD. While both modify disease activity, leflunomide has a distinct mechanism—blocking pyrimidine synthesis—whereas methotrexate inhibits folate metabolism. Choice between them depends on efficacy, tolerability, patient comorbidities and physician preference.

Leflunomide Sandoz tablets should be stored below 25 °C in a dry place. Keep the product in its original packaging, protect it from moisture and excessive heat, and ensure the container is tightly closed to maintain stability.

Leflunomide Sandoz is taken orally as a tablet, usually once daily. It may be taken with or without food, according to the prescriber’s directions. Patients should swallow the tablet whole with water and not split or crush it unless instructed otherwise.

The most serious risks include severe liver injury, life‑threatening infections, bone‑marrow suppression leading to pancytopenia, interstitial lung disease, and teratogenic effects. Patients should report signs of jaundice, persistent fever, unexplained bruising, respiratory symptoms, or any pregnancy‑related concerns immediately.

Leflunomide Sandoz should be avoided by individuals who are pregnant, planning to become pregnant, or breastfeeding. It is also contraindicated in patients with severe hepatic impairment, uncontrolled infections, known hypersensitivity to leflunomide, or those taking certain contraindicated medications.